Our Mission

• To offer portable diagnostic devices to every potential end-user, regardless of financial status, geographical location and training.

• Doctors, healthcare providers and patients in both the developed and developing countries will benefit equally from our technology, which intends to alleviate personal suffering and control disease outbreaks.


Our vision is to become an innovation leader in the field of molecular diagnostics and grow into an international company with significant global presence.


IRIS is a compact device for performing real-time nucleic acid amplification. IRIS was created using threedimensional (3D) additive manufacturing technology and operates via a Smartphone application. 

The device can be used to extract rapidly quantitative information at a wide dynamic range of bacterial DNA, viral RNA and single point mutations. Detection can occur from genomic DNA or directly from crude samples (swabs, saliva and biopsy tissue).

George Papadakis et.al, Real-time colorimetric LAMP methodology for quantitative nucleic acids detection at the point-of-care, BioRxiv 2020

Key features

•Ultra-fast detection time (5 to 20min)
•Use of crude sample (swab, saliva and biopsy tissue)
•Point-of-Care applications

•Battery operated
•Compact size
•Portable lightweight

•Up to 8-sample analysis
•User-friendly operation
•Smartphone application (Android, IOS)


Dr. George Papadakis


Prof. Electra Gizeli


Dr. Alexandros Pantazis

Product Developer

Nikolaos Fikas

Code & Electronics Developer

Sergios Katsaros

Commercial & Finance


02/09/20 – BIOPIX DNA Technology P.C. receives EU funding.

BIOPIX-T (www.biopix-t.com ) is pleased to announce that a consortium of eight partners in which it participated, has been awarded EU funding (2.4M) under the emergency call H2020-SC1-PHE-CORONAVIRUS-2020-2. The aim of the proposal, entitled Market Release of a Portable Device for COVID-19 at the Point-of-Care; a Global Diagnostics Approach” with the acronym “IRIS-COV”is the immediate development, certification and release of BIOPIX-T ‘s novel diagnostic platformIRIS, to carry out a combined test for SARS-CoV2 and Influenza A.  

Read more

23/07/20 – BIOPIX DNA TECHNOLOGY P.C. won at the John and Mary Pappajohn Business Plan Competition

BIOPIX-T was one of the 5 winners, out of 138 teams that participated in the 7th John and Mary Pappajohn Business Plan Competition, organised by the Entrepreneurship Hub at Anatolia College of Thessaloniki! We would like to thank the organisers for an excellent event, despite the pandemic related constraints, and the judges for believing in our project ! 

Read more

20/05/20 – BIOPIX DNA TECHNOLOGY P.C. as a member at Hellenic Biocluster

BIOPIX-T is pleased to announce that it has been accepted as a member of the Hellenic Biocluster. Through the networking and collaborations that this membership will facilitate, we expect to accelerate our market entry both in Greece and abroad.

We would like to thank the management board of HBio for recognizing our technology and our commercial potential and we look forward to actively contributing to the advancement of the Biotech Sector in Greece and Europe.

12/12/19 – BIOPIX DNA TECHNOLOGY P.C. is established

We are happy to announce today the official registration of our company! BIOPIX-T aims to revolutionize molecular diagnostics at the Point-Of-Care and Home-Testing environments on a global scale.

BIOPIX DNA TECHNOLOGY P.C. is a Spin-Off company from the Institute Of Molecular Biology and Biotechnology (IMBB) at the Foundation of Research and Technology Hellas (FORTH).

As a project under the umbrella of FORTH-IMBB, BIOPIX-T was funded by the Patras Science Park under the Proof-of-Concept program which led to the eventual creation of the Spin-Off.

Contact us

100 N. Plastira str. (Science and Technology Park of Crete), GR 70013, Voutes, Greece
VAT no: EL 801269246 – Registry No 153132227000 – 12/12/2019